Selected research
Industry Research
Palonosetron Industry Research Report 2026
Market perspective
The global Palonosetron market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Palonosetron is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Palonosetron is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Palonosetron is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Palonosetron include Teva, Sichuan Hairong Pharmaceutical, Qilu Pharmaceutical, Pfizer, Fresenius Kabi, Jiangsu Aosaikang Pharmaceutical, Sagent Pharmaceuticals, Helsinn Therapeutics and Exela Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Palonosetron market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Palonosetron Market by Company
Teva
Sichuan Hairong Pharmaceutical
Qilu Pharmaceutical
Pfizer
Fresenius Kabi
Jiangsu Aosaikang Pharmaceutical
Sagent Pharmaceuticals
Helsinn Therapeutics
Exela Pharma
Dr. Reddys Laboratories
Cipla
Palonosetron Segment by Type
Injection 0.25 mg/5 mL
Injection 20 mcg/kg (max 1.5 mg)
Palonosetron Segment by Application
Adults
Children
Palonosetron Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Palonosetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Palonosetron and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Palonosetron.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Palonosetron manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Palonosetron by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Palonosetron in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection 0.25 mg/5 mL
- Injection 20 mcg/kg (max 1.5 mg)
Applications
- Adults
- Children
Companies covered
- Teva
- Sichuan Hairong Pharmaceutical
- Qilu Pharmaceutical
- Pfizer
- Fresenius Kabi
- Jiangsu Aosaikang Pharmaceutical
- Sagent Pharmaceuticals
- Helsinn Therapeutics
- Exela Pharma
- Dr. Reddys Laboratories
- Cipla
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Palonosetron Market Size (2021-2032)
- 2.2.2 Global Palonosetron Sales (2021-2032)
- 2.2.3 Global Palonosetron Market Average Price (2021-2032)
- 2.3 Palonosetron by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Injection 0.25 mg/5 mL
- 2.3.3 Injection 20 mcg/kg (max 1.5 mg)
- 2.4 Palonosetron by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Children
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Palonosetron Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Palonosetron Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Palonosetron Revenue of Manufacturers (2021-2026)
- 3.4 Global Palonosetron Average Price by Manufacturers (2021-2026)
- 3.5 Global Palonosetron Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Palonosetron, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Palonosetron, Product Type & Application
- 3.8 Global Manufacturers of Palonosetron, Established Date
- 3.9 Global Palonosetron Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Palonosetron Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sichuan Hairong Pharmaceutical
- 4.2.1 Sichuan Hairong Pharmaceutical Company Information
- 4.2.2 Sichuan Hairong Pharmaceutical Business Overview
- 4.2.3 Sichuan Hairong Pharmaceutical Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sichuan Hairong Pharmaceutical Palonosetron Product Portfolio
- 4.2.5 Sichuan Hairong Pharmaceutical Recent Developments
- 4.3 Qilu Pharmaceutical
- 4.3.1 Qilu Pharmaceutical Company Information
- 4.3.2 Qilu Pharmaceutical Business Overview
- 4.3.3 Qilu Pharmaceutical Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qilu Pharmaceutical Palonosetron Product Portfolio
- 4.3.5 Qilu Pharmaceutical Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Palonosetron Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Fresenius Kabi
- 4.5.1 Fresenius Kabi Company Information
- 4.5.2 Fresenius Kabi Business Overview
- 4.5.3 Fresenius Kabi Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fresenius Kabi Palonosetron Product Portfolio
- 4.5.5 Fresenius Kabi Recent Developments
- 4.6 Jiangsu Aosaikang Pharmaceutical
- 4.6.1 Jiangsu Aosaikang Pharmaceutical Company Information
- 4.6.2 Jiangsu Aosaikang Pharmaceutical Business Overview
- 4.6.3 Jiangsu Aosaikang Pharmaceutical Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Jiangsu Aosaikang Pharmaceutical Palonosetron Product Portfolio
- 4.6.5 Jiangsu Aosaikang Pharmaceutical Recent Developments
- 4.7 Sagent Pharmaceuticals
- 4.7.1 Sagent Pharmaceuticals Company Information
- 4.7.2 Sagent Pharmaceuticals Business Overview
- 4.7.3 Sagent Pharmaceuticals Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Sagent Pharmaceuticals Palonosetron Product Portfolio
- 4.7.5 Sagent Pharmaceuticals Recent Developments
- 4.8 Helsinn Therapeutics
- 4.8.1 Helsinn Therapeutics Company Information
- 4.8.2 Helsinn Therapeutics Business Overview
- 4.8.3 Helsinn Therapeutics Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Helsinn Therapeutics Palonosetron Product Portfolio
- 4.8.5 Helsinn Therapeutics Recent Developments
- 4.9 Exela Pharma
- 4.9.1 Exela Pharma Company Information
- 4.9.2 Exela Pharma Business Overview
- 4.9.3 Exela Pharma Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Exela Pharma Palonosetron Product Portfolio
- 4.9.5 Exela Pharma Recent Developments
- 4.10 Dr. Reddys Laboratories
- 4.10.1 Dr. Reddys Laboratories Company Information
- 4.10.2 Dr. Reddys Laboratories Business Overview
- 4.10.3 Dr. Reddys Laboratories Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Dr. Reddys Laboratories Palonosetron Product Portfolio
- 4.10.5 Dr. Reddys Laboratories Recent Developments
- 4.11 Cipla
- 4.11.1 Cipla Company Information
- 4.11.2 Cipla Business Overview
- 4.11.3 Cipla Palonosetron Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Cipla Palonosetron Product Portfolio
- 4.11.5 Cipla Recent Developments
5 Global Palonosetron Market Scenario by Region
- 5.1 Global Palonosetron Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Palonosetron Sales by Region: 2021-2032
- 5.2.1 Global Palonosetron Sales by Region: 2021-2026
- 5.2.2 Global Palonosetron Sales by Region: 2027-2032
- 5.3 Global Palonosetron Revenue by Region: 2021-2032
- 5.3.1 Global Palonosetron Revenue by Region: 2021-2026
- 5.3.2 Global Palonosetron Revenue by Region: 2027-2032
- 5.4 North America Palonosetron Market Facts & Figures by Country
- 5.4.1 North America Palonosetron Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Palonosetron Sales by Country (2021-2032)
- 5.4.3 North America Palonosetron Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Palonosetron Market Facts & Figures by Country
- 5.5.1 Europe Palonosetron Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Palonosetron Sales by Country (2021-2032)
- 5.5.3 Europe Palonosetron Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Palonosetron Market Facts & Figures by Country
- 5.6.1 Asia Pacific Palonosetron Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Palonosetron Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Palonosetron Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Palonosetron Market Facts & Figures by Country
- 5.7.1 South America Palonosetron Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Palonosetron Sales by Country (2021-2032)
- 5.7.3 South America Palonosetron Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Palonosetron Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Palonosetron Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Palonosetron Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Palonosetron Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Palonosetron Sales by Type (2021-2032)
- 6.1.1 Global Palonosetron Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Palonosetron Sales Market Share by Type (2021-2032)
- 6.2 Global Palonosetron Revenue by Type (2021-2032)
- 6.2.1 Global Palonosetron Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Palonosetron Revenue Market Share by Type (2021-2032)
- 6.3 Global Palonosetron Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Palonosetron Sales by Application (2021-2032)
- 7.1.1 Global Palonosetron Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Palonosetron Sales Market Share by Application (2021-2032)
- 7.2 Global Palonosetron Revenue by Application (2021-2032)
- 7.2.1 Global Palonosetron Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Palonosetron Revenue Market Share by Application (2021-2032)
- 7.3 Global Palonosetron Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Palonosetron Value Chain Analysis
- 8.1.1 Palonosetron Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Palonosetron Production Mode & Process
- 8.2 Palonosetron Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Palonosetron Distributors
- 8.2.3 Palonosetron Customers
9 Global Palonosetron Analyzing Market Dynamics
- 9.1 Palonosetron Industry Trends
- 9.2 Palonosetron Industry Drivers
- 9.3 Palonosetron Industry Opportunities and Challenges
- 9.4 Palonosetron Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst